Cancer is known to be one of the leading causes of deaths worldwide. In fact, as per the WHO, close to 10 million cancer related deaths were reported in 2020. Further, it is estimated that, by the end of 2040, 27.5 million new cancer cases will be added to the global numbers, exerting tremendous physical, emotional and financial strain on affected individuals, their families, communities and national health systems. Although there are several treatment options available to control disease progression and keep malignant cells from spreading throughout the body, lasting remission is difficult to achieve. In this context, immunotherapies, a relatively recent addition to the gamut of anticancer interventions, have demonstrated significant promise. Amidst the current initiatives undertaken to develop more targeted anti-cancer therapies, TCR-based therapies have emerged as a promising option, owing to their tumor-cell killing efficacy may be primarily attributed to the fact that they are pre-sensitized to cancer specific antigens.
TCR Therapies Market – Current Landscape
The TCR therapies landscape features, close to 60 industry players, across the globe claim to be engaged in the development and clinical evaluation of antigen sensitized TCR-based cell therapies. The contemporary TCR therapies market is characterized by a healthy and growing pipeline of more than 190 candidate therapies. Kimmtrak® is the first TCR therapeutic to reach in market. More than 90% of the therapy candidates, which are being developed to target a wide range of disease indications are autologous in nature; NY-ESO-1 and MAGE have emerged as the most popular target antigens
TCR Therapies – Partnerships and Collaborations
A growing interest in this field is reflected from the increase in the partnership activity, involving both international and indigenous stakeholders; majority of such deals were signed between players based in North America; Both established players and new entrants have forged strategic partnerships in the recent past; in fact, more than 35% of the deals were signed in the last four years. Additionally, majority of partnerships are R&D agreements, followed by licensing deals; most of the licensing deals are focused on the licensing of TCR technologies. Further, close to 30% of the deals were signed between players based in North America; examples include Kite Pharma and Juno Therapeutics.
TCR Therapies – Funding and Investments
Several investors, having realized the opportunity within this upcoming segment of T-cell immunotherapy, have invested USD 11 billion, across 140 instances, since 2007
TCR Therapies – Patent Analysis
Majority of the patents in this domain are patent applications (84%), followed by granted patents (13%). In addition, most of the patents (35%) were filed / granted in Asia-Pacific. This is followed by patents filed / granted in North America (30%).
TCR Therapies – Market Forecast and Opportunity Analysis
In the long-term, the overall projected opportunity is likely to be well distributed across key market segments, including type of therapy, indications, target antigen, key players and geographical regions; the market is expected to grow at a CAGR of ~51% by 2035.
Given the recent approval of a TCR therapy, industry stakeholders have initiated several R&D efforts focused on evaluating the potential of such therapy candidates against various disease indications. Moreover, the ongoing research activity in this field has led to the discovery of several novel molecular targets, further strengthening the research pipelines of companies engaged in this market. Several clinical trials have proven the efficacy of TCR-based therapies, presenting lucrative opportunities for the players engaged in the development of these products. Driven by the availability of innovative TCR technology platforms, lucrative funding and encouraging clinical trial results, the TCR-based therapies market is likely to witness significant growth in the mid to long-term.